EPANOVA Drug Patent Profile

« Back to Dashboard

When do Epanova patents expire, and what generic alternatives are available?

Epanova is a drug marketed by Astrazeneca and is included in one NDA. There are four patents protecting this drug.

The generic ingredient in EPANOVA is omega-3-carboxylic acids. Additional details are available on the omega-3-carboxylic acids profile page.

DrugPatentWatch^® Generic Entry Outlook for Epanova

Epanova was eligible for patent challenges on May 5, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 20, 2026. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for EPANOVA

US Patents:	4
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for EPANOVA

EPANOVA is protected by four US patents.

This potential generic entry date is based on patent 7,960,370.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	EPANOVA	omega-3-carboxylic acids	CAPSULE;ORAL	205060-001	May 5, 2014		DISCN	Yes	No	10,117,844
Astrazeneca	EPANOVA	omega-3-carboxylic acids	CAPSULE;ORAL	205060-001	May 5, 2014		DISCN	Yes	No	7,960,370		Y
Astrazeneca	EPANOVA	omega-3-carboxylic acids	CAPSULE;ORAL	205060-001	May 5, 2014		DISCN	Yes	No	9,050,308
Astrazeneca	EPANOVA	omega-3-carboxylic acids	CAPSULE;ORAL	205060-001	May 5, 2014		DISCN	Yes	No	9,050,309			Y

International Patents for EPANOVA

See the table below for patents covering EPANOVA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2013201793
Brazil	112014016788
Canada	2860512
Chile	2014001803

Investment Scenario and Fundamentals Analysis of EPANOVA

Last updated: February 25, 2026

What is EPANOVA?

EPANOVA (ethyl icosapent ethyl) is a purified EPA (eicosapentaenoic acid) formulation approved by the US FDA for reducing cardiovascular risk in select patients. Marketed as VASCEPA in the United States by Amarin Corporation, it addresses hypertriglyceridemia and related cardiovascular conditions.

Market Overview

• Global Market Size: Estimated at $2.4 billion in 2022, expected to grow at approximately 7% annually through 2028.
• US Market: Dominates with a prevalence of hypertriglyceridemia, especially in high-risk cardiovascular patients.
• Regulatory Influence: FDA approval in 2012 for VASCEPA (EPANOVA) bolstered market presence; recent approvals and label expansions enhance or threaten sales.

Competitive Position

Competitors	Key Products	Market Share (Est.)	Notes
Amarin (VASCEPA)	Ethyl icosapent ethyl	60%	FDA-approved, first-mover advantage
Eli Lilly (Epadel)	Prescription omega-3	15%	Approved in some markets, facing regulatory and patent hurdles
Generic omega-3 products	Various, OTC formulations	10%	Lower regulation, lower efficacy claims
Others	Limited commercial success	15%	Niche competitors, mainly in OTC space

Regulatory and Intellectual Property Landscape

• Patent Status: Amarin’s core patents for VASCEPA extend to at least 2030, protecting market exclusivity.
• Regulatory Risks: Pending or future regulatory updates could impact labeling, indications, or approval status globally.
• Off-label Use: No significant off-label markets developed, though monitoring remains essential.

Financial Fundamentals

Revenue Streams

• Product Sales: Primary revenue from VASCEPA sales, $732 million in 2022 globally.
• Royalty Income: Reduced from licensing agreements but still contributes marginally.
• Pipeline Products: Several pipeline candidates in early development or under patent protection.

Cost Structure

• Manufacturing Costs: Approximately 15-20% of revenue, impacted by raw material prices and production scale.
• Marketing & Distribution: Account for roughly 25% of expenses, primarily in the US.
• R&D: Historically 20-25% of revenue annually, focused on expanding indications and formulations.

Profitability Metrics (2022)

Metric	Value	Comments
Gross Margin	68%	High due to specialized formulation
Operating Margin	25%	Reflects significant R&D and marketing expenses
Net Profit Margin	15%	Positivity driven by sales volume

Valuation Indicators

• Market Capitalization: Approximately $4.2 billion.
• Price-to-Sales Ratio: Around 5.7, indicating investor optimism for growth.
• EBITDA Margin: 30%, indicating operational efficiency.

Investment Risks

• Patent Challenges: Potential for patent litigation or challenges could erode exclusivity.
• Regulatory Changes: Future FDA or international regulatory modifications could restrict or expand indications.
• Market Competition: Entry of new omega-3 formulations or alternative lipid-lowering therapies.
• Pricing Pressures: Growing biosimilar or generic alternatives could depress pricing.

Strategic Considerations

• Pipeline Expansion: Development of new formulations and indications, such as heart failure or stroke prevention, could grow revenue.
• Global Expansion: Markets outside the US, notably Europe and Asia, present growth opportunities but face regulatory hurdles.
• Partnerships: Collaborations with biotech or pharma companies could accelerate pipeline development and distribution channels.

Conclusion

EPANOVA (VASCEPA) remains a high-value asset with established cardiovascular benefits, solid patent protection, and steady revenue growth. Its investment outlook relies heavily on regulatory stability, competitive positioning, and successful expansion of indications.

Key Takeaways

• EPANOVA is a market-leading EPA-based treatment approved for cardiovascular risk reduction with growing revenue and robust patent protection.
• The competitive landscape is concentrated, with Amarin holding the majority share, but emerging competition and generics pose threats.
• Financially, the drug exhibits high margins driven by effective manufacturing, marketing, and R&D investments.
• Risks include patent challenges, regulatory shifts, and market competition; strategy should focus on pipeline growth and geographic expansion.

FAQs

1. What is the primary market for EPANOVA?
The US remains the main market, where EPANOVA is approved for reducing cardiovascular risk in patients with elevated triglycerides.

2. How does EPANOVA compare to other omega-3 products?
EPANOVA’s EPA formulation has demonstrated efficacy in cardiovascular risk reduction, unlike some over-the-counter omega-3s that lack robust clinical data.

3. What patent protections does EPANOVA have?
Amarin’s patents extend through at least 2030, covering composition, manufacturing, and indication-specific claims.

4. What are the main growth drivers for EPANOVA?
Pipeline expansion, international regulatory approvals, and increasing cardiovascular disease prevalence are key drivers.

5. What risks could impact EPANOVA’s valuation?
Patent challenges, regulatory restrictions, market competition, and pricing pressures could diminish revenue and profitability.

---

References

1. Amarin Corporation. (2022). Form 10-K. U.S. Securities and Exchange Commission.
2. IBISWorld. (2023). Omega-3 Fatty Acids Industry Report.
3. Statista. (2023). Cardiovascular Disease Market Analysis.
4. FDA. (2019). Approved Drug Label for VASCEPA.
5. GlobalData. (2022). Cardiovascular Disease Market Forecast.